This may have advantages in a cancer setting as multiple roles of IKKα may be involved, but if discrimination between non-canonical NF-κB signalling and other IKKα outputs is the aim, inhibiting its kinase function may not be the answer, and targeting NIK may be the preferred route. Here, CHUK is linked to cancer.